Democratizing access
to Precision Oncology
while improving
patients' lives.

Democratizing access to Precision Oncology while improving patients' lives.

+ Learn more
Precision Oncology

Shifting away from
the one-size-fits-all
approach

Shifting away from the one-size-fits-all approach.

Historically, cancer treatment has relied on a one-size-fits-all approach where drugs and other therapies designed to target large groups of individuals are prescribed based on population parameters, but not on the individual patient’s likelihood of positive response. Precision oncology is here to change that.

Historically, cancer treatment has relied on a one-size-fits-all approach where drugs and other therapies designed to target large groups of individuals are prescribed based on population parameters, but not on the individual patient’s likelihood of positive response. Precision oncology is here to change that.

Our Platform

Providing valuable
insights through
our Drug Activity
Ranking

Providing valuable insights through our Drug Activity Ranking

We're developing a proprietary Drug Activity Ranking to provide oncologists with actionable patient-derived data to aid them in the therapy selection process.

Platform
Capabilites

We're leveraging deep scientific expertise in screening technologies combined with the power of high-throughput flow cytometry to better understand how patients may respond to drugs, before they're actually prescribed.

Our Partners

Resources

Selected Papers

Identification of PLK1 as a therapeutic target in BRCA1-deficient cancers (2019)

In this work we developed a flow-cytometry-based co-culture screening technology for drug discovery, and we used to explore a public kinase inhibitor set.

Bioprospecting South American flora for synthetic lethal lead compounds (2020)

In this work we used our flow-cytometry-based co-culture screening technology to screen a collection of 50 plants species from South America in a wide dose-response scheme.

Screening of regulatory partners of ZEB1 to inhibit its pro-metastatic properties (2019)

In this work we performed In Silico screenings to identifty phosphor regulatory sites of the EMT factor ZEB1 and validated PKCα as a novel partner capable of modulating its premetastatic properties.

Repurposing of breast cancer transcriptomic signature for pan-cancer applications (2020)

In this work we perform studies of correlations of drug sensitivity of a cell line database with transcriptomic classes of cancer cells derived from a commercial breast cancer signature.

Identification of PLK1 as a therapeutic target in BRCA1-deficient cancers (2019)

In this work we developed a flow-cytometry-based co-culture screening technology for drug discovery, and we used to explore a public kinase inhibitor set.

Bioprospecting South American flora for synthetic lethal lead compounds (2020)

In this work we used our flow-cytometry-based co-culture screening technology to screen a collection of 50 plants species from South America in a wide dose-response scheme.

Screening of regulatory partners of ZEB1 to inhibit its pro-metastatic properties (2019)

In this work we performed In Silico screenings to identifty phosphor regulatory sites of the EMT factor ZEB1 and validated PKCα as a novel partner capable of modulating its premetastatic properties.

Repurposing of breast cancer transcriptomic signature for pan-cancer applications (2020)

In this work we perform studies of correlations of drug sensitivity of a cell line database with transcriptomic classes of cancer cells derived from a commercial breast cancer signature.